Treatment of human spasticity with delta 9-tetrahydrocannabinol - PubMed

Clinical Trial

Treatment of human spasticity with delta 9-tetrahydrocannabinol

D J Petro et al. J Clin Pharmacol. 1981 Aug-Sep.

Abstract

Spasticity is a common neurologic condition in patients with multiple sclerosis, stroke, cerebral palsy or an injured spinal cord. Animal studies suggest that THC has an inhibitory effect on polysynaptic reflexes. Some spastic patients claim improvement after inhaling cannabis. We tested muscle tone, reflexes, strength and performed EMGs before and after double-blinded oral administration of either 10 or 5 mg THC or placebo. The blinded examiner correctly identified the trials in which the patients received THC in seven of nine cases. For the group, 10 mg THC significantly reduced spasticity by clinical measurement (P less than 0.01). Quadriceps EMG interference pattern was reduced in those four patients with primarily extensor spasticity. THC was administered to eight other patients with spasticity and other CNS lesions. Responses varied, but benefit was seen in three of three patients with "tonic spasms." No benefit was noted in patients with cerebellar disease.

Similar articles

• Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.

  Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Ungerleider JT, et al. Adv Alcohol Subst Abuse. 1987;7(1):39-50. doi: 10.1300/j251v07n01_04. Adv Alcohol Subst Abuse. 1987. PMID: 2831701 Clinical Trial.

• The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.

  Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J. Ball S, et al. Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120. Health Technol Assess. 2015. PMID: 25676540 Free PMC article. Clinical Trial.

• Sativex^® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial.

  Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, Vila C. Markovà J, et al. Int J Neurosci. 2019 Feb;129(2):119-128. doi: 10.1080/00207454.2018.1481066. Epub 2018 Sep 13. Int J Neurosci. 2019. PMID: 29792372 Clinical Trial.

• A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.

  Arroyo González R. Arroyo González R. Expert Rev Neurother. 2018 Oct;18(10):785-791. doi: 10.1080/14737175.2018.1510772. Epub 2018 Sep 20. Expert Rev Neurother. 2018. PMID: 30235965 Review.

• Medicinal applications of delta-9-tetrahydrocannabinol and marijuana.

  Voth EA, Schwartz RH. Voth EA, et al. Ann Intern Med. 1997 May 15;126(10):791-8. doi: 10.7326/0003-4819-126-10-199705150-00008. Ann Intern Med. 1997. PMID: 9148653 Review.

Cited by

• Cannabinoid receptor localization in brain.

  Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. Herkenham M, et al. Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6. doi: 10.1073/pnas.87.5.1932. Proc Natl Acad Sci U S A. 1990. PMID: 2308954 Free PMC article.

• Pharmacokinetics and pharmacodynamics of cannabinoids.

  Grotenhermen F. Grotenhermen F. Clin Pharmacokinet. 2003;42(4):327-60. doi: 10.2165/00003088-200342040-00003. Clin Pharmacokinet. 2003. PMID: 12648025 Review.

• [Therapeutic use of cannabinoids in neurology].

  Schwenkreis P, Tegenthoff M. Schwenkreis P, et al. Schmerz. 2003 Oct;17(5):367-73. doi: 10.1007/s00482-003-0240-z. Schmerz. 2003. PMID: 14513344 Review. German.

• Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review.

  Mecha M, Carrillo-Salinas FJ, Feliú A, Mestre L, Guaza C. Mecha M, et al. Front Cell Neurosci. 2020 Feb 19;14:34. doi: 10.3389/fncel.2020.00034. eCollection 2020. Front Cell Neurosci. 2020. PMID: 32140100 Free PMC article. Review.

• Structural determinants for recognition and translocation by the anandamide transporter.

  Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, Makriyannis A. Piomelli D, et al. Proc Natl Acad Sci U S A. 1999 May 11;96(10):5802-7. doi: 10.1073/pnas.96.10.5802. Proc Natl Acad Sci U S A. 1999. PMID: 10318965 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database